Tables
- TABLE 1
Summary of the association between short-acting β2-agonist (SABA) overuse (three or more SABA canisters per year compared with fewer than three canisters per year) and exacerbations in a selection of SABA in Asthma (SABINA) programme studies
First author [ref.] Country Population size (n) Prevalence of SABA overuse (% patients) Association between SABA overuse and asthma exacerbations Noorduyn [8] Canada 115 478 SABA overuse was associated with an increased mean±sd exacerbation rate Alberta 107 444 28.0 0.31±0.86 versus 0.17±0.62 Nova Scotia 8034 39.4 0.46±1.11 versus 0.3±1.36 Nwaru [14] Sweden 365 324 30 Positive association observed between number of SABA cannisters issued and exacerbation risk (hazard ratio (95% CI))
≤2 cannisters: 1.003–5 cannisters: 1.26 (1.24–1.28) 6–10 cannisters: 1.44 (1.41–1.46)
≥11 cannisters: 1.77 (1.72–1.83)Bloom [12] UK 574 913 38 SABA overuse was associated with increased risk of exacerbation across asthma severities(adjusted hazard ratio (95% CI))
BTS steps 1 and 2: 1.2 (1.16–1.24)
BTS steps 3–5: 1.24 (1.20–1.28)Bateman [10] Multicountry 8351 38 SABA overuse was associated with increased exacerbation incidence (adjusted incidence rate ratio (95% CI))
3–5 cannisters: 1.40 (1.24–1.58)
6–9 cannisters: 1.52 (1.33–1.74)
10–12 cannisters: 1.78 (1.57–2.02)
≥13 cannisters: 1.92 (1.61–2.29)BTS: British Thoracic Society.
Vol 8 Issue 4
Table of Contents
It is time to end our love affair with short-acting β2-agonists in asthma
